Literature DB >> 11683685

Review article: the pharmacological treatment of acute colonic pseudo-obstruction.

R De Giorgio1, G Barbara, V Stanghellini, M Tonini, V Vasina, B Cola, R Corinaldesi, G Biagi, F De Ponti.   

Abstract

Acute colonic pseudo-obstruction (Ogilvie's syndrome) can be defined as a clinical condition with symptoms, signs and radiological appearance of acute large bowel obstruction unrelated to any mechanical cause. Recent reports of the efficacy of cholinesterase inhibitors in relieving acute colonic pseudo-obstruction have fuelled interest in the pharmacological treatment of this condition. The aim of the present review is to outline current perspectives in the pharmacological treatment of patients with acute colonic pseudo-obstruction. The best documented pharmacological treatment of Ogilvie's syndrome is intravenous neostigmine (2-2.5 mg), which leads to quick decompression in a significant proportion of patients after a single infusion. However, the search for new colokinetic agents for the treatment of lower gut motor disorders has made available a number of drugs that may also be therapeutic options for Ogilvie's syndrome. Among these agents, the potential of 5-hydroxytryptamine-4 receptor agonists and motilin receptor agonists is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683685     DOI: 10.1046/j.1365-2036.2001.01088.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  24 in total

Review 1.  Advances in our understanding of the pathology of chronic intestinal pseudo-obstruction.

Authors:  R De Giorgio; G Sarnelli; R Corinaldesi; V Stanghellini
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

2.  Effect of polyethylene glycol electrolyte balanced solution on patients with acute colonic pseudo obstruction after resolution of colonic dilation: a prospective, randomised, placebo controlled trial.

Authors:  S N Sgouros; J Vlachogiannakos; K Vassiliadis; C Bergele; G Stefanidis; H Nastos; A Avgerinos; A Mantides
Journal:  Gut       Date:  2005-11-23       Impact factor: 23.059

3.  Intestinal pseudo-obstruction: an uncommon condition with heterogeneous etiology and unpredictable outcome.

Authors:  Eugen Florin Georgescu; Ion Vasile; Reanina Ionescu
Journal:  World J Gastroenterol       Date:  2008-02-14       Impact factor: 5.742

Review 4.  Chronic intestinal pseudo-obstruction.

Authors:  Alexandra Antonucci; Lucia Fronzoni; Laura Cogliandro; Rosanna-F Cogliandro; Carla Caputo; Roberto De Giorgio; Francesca Pallotti; Giovanni Barbara; Roberto Corinaldesi; Vincenzo Stanghellini
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

5.  Wilkie or Ogilvie?

Authors:  Avi Ohry
Journal:  Spinal Cord Ser Cases       Date:  2018-10-27

Review 6.  Acute colonic pseudoobstruction.

Authors:  Allen P Chudzinski; Earl V Thompson; Jennifer M Ayscue
Journal:  Clin Colon Rectal Surg       Date:  2015-06

7.  Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine.

Authors:  Seung-Ah Yahng; Jae-Ho Yoon; Seung-Hwan Shin; Sung-Eun Lee; Ki-Seong Eom; Yoo-Jin Kim
Journal:  Blood Res       Date:  2013-06-25

8.  Neostigmine treatment protocols applied in acute colonic pseudo-obstruction disease: A retrospective comparative study.

Authors:  Ömür İlban; Faruk Çiçekçi; Jale Bengi Çelik; Mehmet Ali Baş; Ateş Duman
Journal:  Turk J Gastroenterol       Date:  2019-03       Impact factor: 1.852

9.  Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.

Authors:  G Parthasarathy; K Ravi; M Camilleri; C Andrews; L A Szarka; P A Low; A R Zinsmeister; A E Bharucha
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

10.  Treatment of pediatric Ogilvie's syndrome with low-dose erythromycin: a case report.

Authors:  Da-Peng Jiang; Zhao-Zhu Li; Sheng-Yang Guan; Yu-Bo Zhang
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.